Myeloperoxidase (MPO) - possible diagnosis biomarker and risk stratification in myocardial inotropism deficit induced by chronic ischemic heart disease

The myeloperoxidase levels of 208 patients with ischemic heart disease hospitalized for congestive heart failure were tested at admission, and discharge after 14 days. The calculations for the serum average concentration/lot/date, were made, subsequent, using the values of the tested parameters regarding MPO (admission and discharge) the mean concentration/lot was made, regardless of time of determination. The calculated average values analyses of the three MPO serum parameters were constantly elevated and permanently matched the myocardial contractility deficiency class. The integrated data of the study, allows us to propose the MPO’s circulating concentration as a diagnosis and risk assessment biomarker in the etiology of myocardial ischemia for chronic cardiac failure.

Serum Concentration of hsCRP - Possible Marker for Therapy Evaluation in Left Ventricular Dysfunction with Preserved Ejection Fraction

The study on a subset of 208 patients with diastolic dysfunction with the ejection fraction preserved discusses the possibility of circulating CRP levels to be accepted as a diagnostic marker. In order to carry out a comparative analysis of the significance of hsCRP serum values, the study also included a subgroup labeled as control, consisting of the same number of patients, but diagnosed only with painful chronic ischemic cardiopathy - a stable form of angina pectoris. The conclusion of the study is that the circulating level of hs-CRP can be accepted as a diagnostic marker for both ischemic cardiopathy and diastolic dysfunction with preserved ejection fraction. The result, corroborated with data from other studies that recognize the serum concentration of hs-CRP as a predictor marker in cardiovascular disease, supports its usefulness as a marker for cardiac insufficiency with a history of ischemic cardiopathy, without being a marker for assessing the degree of myocardial contractility deficiency.